Access to Pharmaceutical Patents in the COVID-19 Emergency: A Case for Government Use in Nigeria. (December 2021)

• Record Type: Journal Article
• Authors: Adewopo, Adebambo
• Editors: Durojaye, Ebenezer; Lwabukuna, Olivia; Oette, Lutz; Williams-Elegbe, Sope
• Is Part Of: Journal of African law. Volume 65(2021)Supplement 2
• Page Start: 259
• Page End: 286
• Publication Date: 2021-12
• Subjects: Pharmaceutical patent -- public health -- COVID-19 vaccines -- compulsory licence -- government use -- Patents and Designs Act; Law -- Africa -- Periodicals; 349.605
• DOI: 10.1017/S0021855321000334
• Languages: English
• ISSNs: 0021-8553

Abstract

Abstract: The COVID-19 pandemic has continued to exert enormous pressure on public health policies and systems, with far-reaching implications. The race for vaccines has raised important intellectual property rights issues. These are evident in the need to advance the public interest and in the obligation of governments to address the challenge of access to vaccines, especially in sub-Saharan countries like Nigeria with relatively underdeveloped healthcare and innovation ecosystems. While the Nigerian Patents and Designs Act (PDA) establishes a compulsory licence regime that affords access to patented drugs, existing public healthcare is severely challenged in providing access to new medicines. This article examines the framework for patent protection of pharmaceuticals designed to meet public health challenges, such as those presented by the pandemic. It recommends the implementation of a government use provision under the PDA, with a view to addressing the challenge of access to COVID-19 vaccines.